Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim A Papp

Showing results (61-70 of 219) with videos related to

Pageof 22
Sort By:
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part IIKim A Papp, Charles Camisa, Stephen P Stone, et al.
JAMA|December 18, 2003
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, et al.
Journal of the American Academy of Dermatology|March 22, 2018
Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysisAlice B Gottlieb, Kim A Papp, Charles A Birbara, et al.
Journal of Cutaneous Medicine and Surgery|October 31, 2017
A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in AdultsCharles W Lynde, Marc Bourcier, Melinda Gooderham, et al.
Journal of Cutaneous Medicine and Surgery|June 6, 2020
Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus PaperJensen Yeung, Melinda J Gooderham, Parbeer Grewal, et al.
Journal of the American Academy of Dermatology|October 22, 2011
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasisDavid M Pariser, Craig L Leonardi, Kenneth Gordon, et al.
Dermatology and Therapy|August 8, 2024
Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK InhibitorsMark G Kirchhof, Vimal H Prajapati, Melinda Gooderham, et al.
RMD Open|June 14, 2022
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2Andrew J K Ostor, Ahmed M Soliman, Kim A Papp, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2017
Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical TrialMichael Eberhardson, Stephen Hall, Kim A Papp, et al.
Expert Opinion on Investigational Drugs|February 10, 2026
Pharmacokinetics and safety of candidate biosimilar CTP55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, phase I studyTomoko Hasunuma, Michio Yagi, Noboru Nakamichi, et al.
Pageof 22

Showing results (61-70 of 219) with videos related to

Sort By:
Pageof 22
Journal of Cutaneous Medicine and Surgery|May 16, 2006
Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part IIKim A Papp, Charles Camisa, Stephen P Stone, et al.
JAMA|December 18, 2003
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trialKenneth B Gordon, Kim A Papp, Tiffani K Hamilton, et al.
Journal of the American Academy of Dermatology|March 22, 2018
Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysisAlice B Gottlieb, Kim A Papp, Charles A Birbara, et al.
Journal of Cutaneous Medicine and Surgery|October 31, 2017
A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in AdultsCharles W Lynde, Marc Bourcier, Melinda Gooderham, et al.
Journal of Cutaneous Medicine and Surgery|June 6, 2020
Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus PaperJensen Yeung, Melinda J Gooderham, Parbeer Grewal, et al.
Journal of the American Academy of Dermatology|October 22, 2011
Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasisDavid M Pariser, Craig L Leonardi, Kenneth Gordon, et al.
Dermatology and Therapy|August 8, 2024
Practical Recommendations on Laboratory Monitoring in Patients with Atopic Dermatitis on Oral JAK InhibitorsMark G Kirchhof, Vimal H Prajapati, Melinda Gooderham, et al.
RMD Open|June 14, 2022
Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2Andrew J K Ostor, Ahmed M Soliman, Kim A Papp, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 11, 2017
Safety and Immunogenicity of Inactivated Varicella-Zoster Virus Vaccine in Adults With Autoimmune Disease: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical TrialMichael Eberhardson, Stephen Hall, Kim A Papp, et al.
Expert Opinion on Investigational Drugs|February 10, 2026
Pharmacokinetics and safety of candidate biosimilar CTP55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, phase I studyTomoko Hasunuma, Michio Yagi, Noboru Nakamichi, et al.
Pageof 22